BNTX - BioNTech to set up mRNA Excellence Center in Israel for research with Weizmann Institute

• BioNTech ( NASDAQ: BNTX ) said it will set up an mRNA Excellence Center to conduct research with scientists at the Weizmann Institute of Science in Israel.
• The German mRNA COVID vaccine maker signed a Memorandum of Understanding (MoU) with Weizmann under which scientists from a variety of disciplines from the two parties will collaborate to better understand various diseases, including cancer, infectious and neurodegenerative diseases.
• The research will be conducted at BioNTech's newly established mRNA Excellence Center, based within the Weizmann Science Park in Ness Ziona, and in Weizmann Institute laboratories.
• The company expects to lease office and laboratory space for the center which is anticipated to provide space for about 60 researchers.
• BioNTech expects the center to begin operations by the end of this year.
• In addition, BioNTech noted that it intends to set up and operate an mRNA manufacturing facility based on its BioNTainer solution in Israel. The facility would be aimed at developing investigational cancer therapies and help Israel respond to potential health threats.
• BNTX -1.42% to $128.20 premarket March 1

For further details see: